NEW YORK (360Dx) – Lucence Diagnostics said today that it is teaming with Stanford University School of Medicine to develop artificial intelligence algorithms for improving diagnosis and treatment of liver cancer by analyzing both imaging and molecular data.
In conjunction with Stanford biomedical informatician Olivier Gevaert, Singapore-based Lucence will process a dataset of more than 5,000 patients with liver cancer to look for changes and patterns in imaging and mutations that could predict the effectiveness of a therapy. The partners will rely on Lucence's LiquidHallMark, a blood test that analyzes the DNA of cancer-related mutations and viral targets.
"By combining radiology with our proprietary sequencing technology and track record in liver cancer data modeling, our AI algorithms will assist physicians in making better treatment decisions," Lucence Diagnostics Founder and CEO Min-Han Tan said in a statement.